https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50027 Wed 28 Jun 2023 09:28:42 AEST ]]> Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43081 Tue 13 Sep 2022 12:19:26 AEST ]]> Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10494 Sat 24 Mar 2018 08:08:58 AEDT ]]> Current opinion on optimal treatment for colorectal cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20065 Fri 21 Aug 2015 13:38:26 AEST ]]>